Bicara Therapeutics Inc. (BCAX) stock
Close on Nov 11, 2026Market cap $696.80MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $696.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.70
- Dividend yield
- –
- Free cash flow yield
- -23.36%
Fundamentals
- Net income
- -$220.28M
- EPS, diluted
- -$2.52
- Free cash flow
- -$162.75M
- Book value per share
- $5.99
- Diluted shares
- 68M
Trading
- Next earnings
- Mar 29, 2027 (estimated, before the open)
- Previous close
- $10.18
- Open
- $10.35
- Day's range
- $10.11 – $11.45
- Volume
- 1,506,163
- Average volume (20 days)
- 2,140,999
- Index membership
- Russell 2000 (since Dec 2024), Russell 3000 (since Nov 2024)
- Beta (5 years)
- 1.58
- 52-week range
- $7.87 – $30.99
- RSI (14 days)
- 35.9
- Volatility (1 year)
- 73.7%
- Relative volume
- 1.53×
- WACC
- 12.8%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCAX | S&P 500 | Difference | BCAX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -39.8% | -2.4% | −37.4 pts | ||
| 3 months | -55.7% | -1.2% | −54.5 pts | ||
| Year to date | -37.4% | +12.3% | −49.7 pts | ||
| 1 year | -28.5% | +12.4% | −41.0 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bicara Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of DirectorsUpdate
- News
- Results
- Results
About Bicara Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical firm developing bifunctional therapies for patients with solid tumors. Its platform combines tumor-targeting antibodies with modulating agents to deliver localized treatment within the tumor microenvironment. The lead product candidate, ficerafusp alfa, is a bifunctional antibody designed to inhibit epidermal growth factor receptors while neutralizing transforming growth factor beta. This therapy primarily targets head and neck squamous cell carcinomas, alongside other solid tumors such as colorectal, cutaneous squamous cell, and anal squamous cell cancers. The company serves patients with advanced, recurrent, or metastatic solid malignancies.
Company profile, executives and historyBicara Therapeutics stock: common questions
What is Bicara Therapeutics's stock price?
BCAX closed at $10.53 on Nov 11, 2026, up 3.44% on the day. Over the past 52 weeks it traded between $7.87 and $30.99.
What is Bicara Therapeutics's market cap?
Bicara Therapeutics was worth $696.80M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BCAX's P/E ratio?
Bicara Therapeutics lost money over fiscal 2025 (diluted EPS -$2.52), so it has no meaningful P/E ratio.
Does Bicara Therapeutics pay a dividend?
No. Bicara Therapeutics has not paid a cash dividend over the last twelve months.
When does Bicara Therapeutics report earnings next?
Bicara Therapeutics is expected to report Q4 FY2026 results on Mar 29, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BCAX stock performed over the past year?
Including dividends, BCAX returned -28.5% over the past year, against +12.4% for the S&P 500.
How many BCAX shares are sold short?
10M shares were sold short at the latest FINRA report, 20.06% of the float, or 3.8 days of average trading volume.
Who are Bicara Therapeutics's competitors?
Companies most similar to Bicara Therapeutics by business, industry and size include PYXS, SMMT, AVBP, CBIO, NXTC.
See a number that looks wrong?